Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
Clinical trial NCT03575065 · COMPLETED
Trial details
- NCT number
- NCT03575065
- Sponsor
- BeiGene
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-22
- Primary completion
- 2020-10-09
- Enrollment
- 88
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.